Safety Market Fit Leverage Buzzkill Labs' rapid saliva THC impairment test to target safety-sensitive employers seeking fast, on-site decision making. Potential customers include manufacturing, logistics, transportation, healthcare, and other industries with strict impairment policies. Opportunity to integrate with HRIS/EHS systems and to reduce downtime while improving compliance and safety outcomes.

Funding Momentum The oversubscribed Series A and board appointment signal strong growth momentum and access to an investor network for partnerships and co selling. Use Poseidon and board contacts to establish distribution alliances, pilot programs, and strategic collaborations with related life sciences and cannabis sector players.

First Mover Advantage Position as the world's first rapid saliva test that detects workday impairment rather than past use, offering a differentiator against legacy immunoassay approaches. Focus on credibility, regulatory alignment, and early pilots with high visibility customers to validate performance and speed.

Strategic Partnerships With a lean team, accelerate deployment through channel partners such as cannabis retailers, testing laboratories, safety training providers, and occupational health networks. Consider white-labeling, data collaboration, and integration with existing drug-testing ecosystems and EHS software vendors.

Enterprise Revenue Model Tap into enterprise contracts, consumables or service agreements, and data management offerings as scalable revenue streams. Develop pilot programs, tiered pricing, and expansion plans into adjacent markets such as regulated cannabis compliance and occupational health testing to fuel growth.